SAB BIO Appoints Lucy To as Chief Financial Officer
SAB Biotherapeutics (Nasdaq: SABS) has appointed Lucy To as Chief Financial Officer, effective August 12, 2024. With over 18 years of investment banking and strategic operational expertise, Ms. To will lead corporate finance, strategy, and strategic business relationships at SAB. The company is developing human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D).
SAB's CEO, Samuel J. Reich, expressed confidence in Ms. To's ability to contribute to the company's upcoming milestones for SAB-142, their lead candidate. Ms. To, previously a Managing Director in the Healthcare Investment Banking Group at Wells Fargo, brings extensive experience in M&A, IPOs, and other equity and debt financings in the healthcare sector, with transactions totaling over $50 billion.
SAB Biotherapeutics (Nasdaq: SABS) ha nominato Lucy To come Chief Financial Officer, a partire dal 12 agosto 2024. Con oltre 18 anni di esperienza in investment banking e competenze operative strategiche, la signora To guiderà la finanza aziendale, la strategia e le relazioni commerciali strategiche presso SAB. L'azienda sta sviluppando immunoglobulina anti-timocitaria umana (hIgG) per ritardare l'insorgenza o la progressione del diabete di tipo 1 (T1D).
Il CEO di SAB, Samuel J. Reich, ha espresso fiducia nella capacità della signora To di contribuire ai prossimi traguardi dell'azienda per SAB-142, il loro principale candidato. La signora To, in precedenza Managing Director del Healthcare Investment Banking Group di Wells Fargo, porta con sé un'ampia esperienza in fusioni e acquisizioni, IPO e altri finanziamenti azionari e debitori nel settore sanitario, con transazioni per un totale di oltre 50 miliardi di dollari.
SAB Biotherapeutics (Nasdaq: SABS) ha nombrado a Lucy To como Directora Financiera, con efecto a partir del 12 de agosto de 2024. Con más de 18 años de experiencia en banca de inversión y en operaciones estratégicas, la Sra. To liderará las finanzas corporativas, la estrategia y las relaciones comerciales estratégicas en SAB. La compañía está desarrollando inmunoglobulina anti-timocitaria humana (hIgG) para retrasar la aparición o progresión de diabetes tipo 1 (T1D).
El CEO de SAB, Samuel J. Reich, expresó confianza en la capacidad de la Sra. To para contribuir a los próximos hitos de la empresa para SAB-142, su candidato principal. La Sra. To, anteriormente Directora Ejecutiva en el Healthcare Investment Banking Group de Wells Fargo, aporta una amplia experiencia en fusiones y adquisiciones, OPI y otros financiamientos de capital y deuda en el sector salud, con transacciones por un total de más de 50 mil millones de dólares.
SAB 바이오테라퓨틱스(Nasdaq: SABS)는 Lucy To를 최고 재무 책임자로 임명했다고 발표했습니다. 임기는 2024년 8월 12일부터 시작됩니다. 18년 이상의 투자은행 및 전략적 운영 경험을 보유한 To 부사장은 SAB에서 기업 재무, 전략 및 전략적 비즈니스 관계를 이끌게 됩니다. 이 회사는 인간 항흉선 면역글로불린(hIgG)을 개발 중이며, 이는 1형 당뇨병(T1D)의 발병 또는 진행을 지연시키기 위한 것입니다.
SAB의 CEO인 Samuel J. Reich는 To 부사장이 SAB-142, 그들의 주요 후보의 향후 이정표에 기여할 수 있는 능력에 대한 신뢰를 표명했습니다. To 부사장은 이전에 웰스 파고의 의료 투자은행 그룹에서 매니징 디렉터로 활동했으며, 500억 달러 이상의 거래를 포함한 의료 분야의 M&A, IPO 및 기타 자본 및 부채 금융에 대한 광범위한 경험을 갖추고 있습니다.
SAB Biotherapeutics (Nasdaq: SABS) a nommé Lucy To au poste de Directrice financière, à compter du 12 août 2024. Forte de plus de 18 ans d'expérience en banque d'investissement et en opérations stratégiques, Mme To dirigera la finance d'entreprise, la stratégie et les relations commerciales stratégiques chez SAB. L'entreprise développe l'immunoglobuline anti-thymocyte humaine (hIgG) pour retarder l'apparition ou la progression du diabète de type 1 (T1D).
Le PDG de SAB, Samuel J. Reich, a exprimé sa confiance dans la capacité de Mme To à contribuer aux prochaines étapes clés de l'entreprise concernant SAB-142, leur principal candidat. Mme To, qui était auparavant Managing Director dans le groupe de banque d'investissement en santé de Wells Fargo, dispose d'une vaste expérience en fusions et acquisitions, OPA et autres financements en actions et en dette dans le secteur de la santé, avec des transactions totalisant plus de 50 milliards de dollars.
SAB Biotherapeutics (Nasdaq: SABS) hat Lucy To zur Chief Financial Officer ernannt, ab dem 12. August 2024. Mit über 18 Jahren Erfahrung im Investment Banking und in strategischen Betriebsabläufen wird Frau To die Unternehmensfinanzierung, Strategie und strategische Geschäftsbeziehungen bei SAB leiten. Das Unternehmen entwickelt humane Anti-Thymozyten-Immunglobuline (hIgG), um den Beginn oder das Fortschreiten von Typ-1-Diabetes (T1D) zu verzögern.
Der CEO von SAB, Samuel J. Reich, äußerte Vertrauen in die Fähigkeit von Frau To, zu den kommenden Meilensteinen des Unternehmens für SAB-142, ihren Hauptkandidaten, beizutragen. Frau To war zuvor Managing Director in der Healthcare Investment Banking Group von Wells Fargo und bringt umfassende Erfahrung in M&A, IPOs und anderen Eigen- und Fremdfinanzierungen im Gesundheitssektor mit, wobei die Transaktionen über 50 Milliarden Dollar betrugen.
- Appointment of experienced CFO with 18 years of investment banking and strategic operational expertise
- Expected top-line Phase 1 data for lead candidate SAB-142 in T1D by end of 2024
- New CFO brings extensive transaction experience in M&A, IPOs, and financings worth over $50 billion
- None.
MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Lucy To has been named Chief Financial Officer effective August 12, 2024. Ms. To brings over 18 years of investment banking and strategic operational expertise to SAB and will lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company.
“Lucy’s proven track record and experience will prove invaluable to SAB as we continue to deliver on our upcoming milestones for SAB-142,” notes Samuel J. Reich, Chairman and CEO of SAB. “I’m thrilled to welcome her to our team and look forward to her impact on the organization as we deliver value to our shareholders and transform the landscape of T1D.”
"I am incredibly excited to join the SAB team during this transformational time for the company where we expect top-line Phase 1 data for our lead candidate, SAB-142, in T1D by the end of 2024," said Ms. To. "The opportunity to work at a company that has the potential to generate best-in-disease data, transform the T1D landscape significantly, and alter the course of this complex and life-threatening autoimmune disease is highly attractive. I look forward to being a part of this stellar team and contributing in the effort to make SAB's therapies a reality for patients."
Prior to joining SAB, she was a Managing Director in the Healthcare Investment Banking Group at Wells Fargo where she advised biopharmaceutical companies on financing and strategic transactions. Her career experience includes additional investment banking and operational experience at Deutsche Bank, Intercept Pharmaceuticals, Citigroup, and Cowen. Her transaction experience includes M&A, IPOs and other equity and debt financings in the healthcare sector with an aggregate transaction value in excess of
About SAB BIO
SAB BIO (SAB) is a clinical-stage biopharmaceutical company focused on developing human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets T1D with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAb™ drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors. For more information on SAB, visit: https://www.SAB.bio/ and follow SAB on Twitter and LinkedIn.
Forward-Looking Statements
Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the development and efficacy of our T1D program and other discovery programs.
These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
CONTACTS
Media Relations:
khollon@sab.bio
Investor Relations:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
FAQ
Who is the new CFO of SAB Biotherapeutics (SABS)?
What is SAB Biotherapeutics (SABS) developing?
When does SAB Biotherapeutics (SABS) expect top-line Phase 1 data for SAB-142?
What is Lucy To's background before joining SAB Biotherapeutics (SABS)?
